Sponsored Content
Vienna International Health and Pharmaceutical Industry News
Read the latest headlines about the Viennese and Austrian health and pharmaceuticals industry
Sponsored Content
Austria at Medical Fair Asia 2012
Top medical products “made in Austria” at MEDICAL FAIR ASIA and MEDICAL MANUFACTURING ASIA 2012 from September 12 2012 to September 14 2012 in Singapore.
August 20, 2012
Sponsored Content
U.S. Forest Laboratories Cooperates with Nabriva
The U.S. pharmaceutical company provides funds of $ 25m to the Austrian Nabriva and secures pre-emptory rights.
June 2, 2012
Sponsored Content
Baxter Enlarges Viennese Site
The U.S. pharmaceutical group makes investments of € 30m in Vienna. The start of operation of a new production facility is planned in 2014.
May 18, 2012
Intercell Completes Equity Private Placement
The Austrian pharmaceutical company raises funds of € 15.2m at a price of € 2.30 per new share - bringing total volume of combined debt and equity financing to € 35.2m.
May 15, 2012
Sponsored Content
Intercell Remains in the Loss Area
The Austrian pharmaceutical company recorded a net loss of € 8.1m in the first quarter of 2012 after € 11.3m in the first quarter of 2011.
May 8, 2012
Canadian Valeant Buys Assets of Gerot Lannach
The Austrian drugmaker Gerot Lannach sells its acetylsalicylic acid business in Russia. The sale price amounts to $ 185m.
March 13, 2012
Sanochemia Announced Scanlux Market Entry in Columbia
The Austrian pharmaceutical company announced the market entry of Scanlux in Columbia. Further approvals are targeted in Costa Rica, El Salvador, Venezuela and Paraguay.
March 7, 2012
Intercell Does Not Leave the Loss zone
The Austrian pharmaceutical company announces preliminary full year 2011 financial results. Losses totaled € 29m.
March 6, 2012
Slight Improvement in Sanochemia´s Results
The Austrian pharmaceutical company could increase sales by 12% in the first quarter of 2011/12. Sanochemia could reach small profits again.
February 15, 2012
Sponsored Content
Intercell Plans to Achieve Turnaround in 2014
The Vienna-listed pharmaceutical company Intercell expects to return to the profit zone in 2014.
February 6, 2012
Slightly Positive Results at Sanochemia
The Austrian pharmaceutical company raised revenues by 26%. Profits amount to € 0.7m.
January 26, 2012
Too Little Competition for Energy and Pharmaceuticals
According to the Austrian institute of economic research (WIFO), electricity, energy and pharmaceuticals are too expensive.
January 2, 2012
New Chairman for Intercell’s Supervisory Board
Thomas Szucs succeeds Michael Gréco who remains on the Supervisory Board of the Austrian pharmaceutical company.
December 30, 2011
Sanochemia Achieves Turnaround
The Austrian pharmaceutical company could turn net results and EBIT into the profit zone. Sales were up too.
December 19, 2011
Sponsored Content
Intercell Receives Approval for Vaccine in India
The Austrian pharmaceutical company achieved an important milestone in the roll-out of its Japanese Encephalitis vaccine in endemic countries.
November 10, 2011
Intercell Still Reports Losses
The Austrian pharmaceutical company could reduce its net losses from € 50.8m to € 20.62m. For the full year the net loss expectations ranges up to € 40m.
November 8, 2011
Full Order Books For VTA
The Austrian water technology company expects a substantial rise in sales for 2012. Recently an order from Indonesia has been recorded.
October 30, 2011
Intercell Continues Development of Vaccines
The Austrian pharmaceutical company announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections.
October 24, 2011
Intercell: EU Invests € 30m in Research Program
The Austrian pharmaceutical company will receive co-funding for a collaborative research project from the European Union.
September 29, 2011
Sponsored Content
Intercell Looking for Private Equity Shareholder
According to Bloomberg, the Austrian pharmaceutical company negotiates with potential investors in order to strengthen the equity base.
September 27, 2011
Sanochemia´s Purchase of Alvetra & Werfft Completed
The Austrian pharmaceutical group acquires the former subsidiary again for € 5.2m.
September 21, 2011
Intercell Successfully Completes Vaccine Study in India
The Austrian biotech company achieved an important step in the licensure process of a vaccine for children.
September 16, 2011
Upper Austrian PAA Laboratories Acquired by GE Healthcare
The Pasching-based cell culture company will combine with the global provider of medical technologies and services. The deal is expected to close in the third quarter.
August 18, 2011
Intercell: Restructuring Is Progressing
Sales of the company’s only product on the market increased by 85% in the first six months of the year. Net loss was down 44.2%.
August 16, 2011
Sponsored Content
ugichem Closes € 2m Financing Round
The Tyrolean biotech company secured funding from two major investors and a research grant from the Austrian Research Promotion Agency.
August 9, 2011
Intercell Is Looking for Financial Investors
The ailing Austrian biotech company is in urgent need of cash. An acquisition, strategic partnerships and a capital increase are being evaluated.
July 19, 2011
Intercell: “We Will Stabilize Our Share Price”
The Austrian biotech company recorded a dramatic drop in its share price. The CEO remains optimistic and promises stabilization.
June 21, 2011
Intercell to Cut Jobs and Research Budget
The share price plunged by more than 30% after the Austrian pharmaceutical company had announced the termination of a vaccine study.
June 8, 2011
Sanochemia Confirms the Turnaround and Returns to Profitability
Sanochemia reports a profit and puts the focus on market expansion. Revenue increased by 20 percent year-on-year.
May 13, 2011
Sponsored Content
Intercell: Sale Is No Longer Ruled Out
The new CEO of the Austrian pharmaceutical company, Thomas Lingelbach intends to implement a new strategy for the company. A sale is possible.
May 11, 2011
Lingelbach New CEO for Intercell
Intercell announces new management structure: Thomas Lingelbach appointed new CEO; new Supervisory Board members proposed.
May 5, 2011
Intercell starts a confirmatory clinical study using the Vaccine Enhancement
Intercell starts clinical trial in Pandemic Influenza with its Vaccine Enhancement Patch and provides update to the strategic collaboration with GSK on patches
May 4, 2011
Sanochemia: Capital Increase Disappointing
The Austrian pharmaceutical company could not meet its own expectations regarding the capital increase. A strategic investor bailed out.
April 18, 2011
Intercell: Vaccine Development to Suspend
Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710. The share of Intercell crashed seriously.
April 11, 2011
Sponsored Content
Intercell Announces next Steps of Development for Pseudomonas Vaccine
Today Intercell AG announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU (Intensive Care Unit) patients.
April 2, 2011
Record Sales for VAMED AG
The Austrian health care group was able to increase sales and EBIT by 15%. Orders on hand at over € 800m are record high.
March 25, 2011 · Updated: March 25, 2011; 03:24
Lannacher has Delivery Problems with Iodine Tablets
The Austrian pharmaceutical company manufactures the only potassium iodide tablets in the German-speaking area. Demand strongly exceeds production capacity.
March 18, 2011
Opportunities for Austrian Medical Technology in the UK
An Austrian study showed Austrian buinesses the opportunities offered by the British market: Austrian exports increased by 15% in 2010.
March 17, 2011
Massive Losses for Intercell
The Austrian pharmaceutical company today reported losses for 2010 amounting to € 255m. Operating cash flow has been strongly negative too.
March 2, 2011
Sponsored Content
Intercell Issues Convertible Bond
The Austrian pharmaceutical company Intercell starts offering of € 30.8m senior convertible debt financing.
February 23, 2011
Sanochemia: Strong Increase in EBIT
The Austrian pharmaceutical company today announced its figures for Q1. Earnings rise eight-fold.
February 18, 2011
Sanochemia Stays in the Red
Despite improvements in its financial data, the Austrian pharmaceutical company Sanochemia does not succeed in eliminating its losses
January 28, 2011
Humanomed to Expand to CEE/SEE
The Austrian Humanomed-Group, a health care company, sees potential to expand to countries in (South) Eastern Europe.
January 28, 2011
Sanochemia Takes Over Alvetra & Werfft
The Austrian pharmaceutical company Sanochemia strengthens its market position through the acquisition of Alvetra & Werfft GmbH.
January 25, 2011
Pfizer Austria: First Sustainability Report Published
Pfizer Austria published its first sustainability report based on the recognized guidelines of the Global Reporting Initiative.
January 20, 2011
Sanochemia: Decrease in Sales, Decrease in Losses
The Vienna Stock Exchange listed manufacturer of pharmaceutical products could improve its results slighty.
January 3, 2011
Intercell Raises Authorized Capital
The Management Board of the Austrian biotechnology company is authorized to increase the share capital up to a nominal amount of € 855,000.00.
December 16, 2010
Serious setback for Intercell
The Vienna vaccine manufacturers has to terminate a research project unexpectedly at a late stage. Heavy losses are expected for this year.
December 14, 2010
Economic Chamber in Tokyo: Biotechnology as an Opportunity
The President of the Vienna Economic Chamber, Brigitte Jank, sees above all great opportunities for Austria in Japanese biotechnology and pharmaceutical industries.
December 6, 2010
Expansion Potential of Austrian Pharmaceutical Industry in Japan
Japanese pharmaceutical companies need new products and international cooperation. An opportunity for local companies.
December 1, 2010
Sponsored Content
Fast News Search
This category only
